As part of a strategy to strengthen its immunology segment through acquisitions, Sanofi has agreed to buy US-based Blueprint ...

France's Sanofi has agreed to buy US-based Blueprint Medicines Corp. for over $9 billion to boost its position in rare ...

In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying ...

Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic mastocytosis (SM), a rare immunological disease, and other ...

Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology <l ...

France's Sanofi has agreed to buy U.S.-based Blueprint Medicines Corporation for up to $9.5 billion to boost its position in ...

France's Sanofi has agreed to buy U.S.-based Blueprint Medicines Corporation for over $9 billion to boost its position in ...

French pharma group Sanofi has agreed to buy US-based Blueprint Medicines Corporation, a biopharmaceutical company ...

(Reuters) -Regeneron shares fell nearly 13% before the bell on Friday after its experimental drug for patients with a type of ...

Recent research from Sanofi highlights the significant impact of Type 1 Diabetes on those living with the conditionThe song, "Rise Up," shares their experiences of living with the condition ...

This browser is no longer supported at MarketWatch. For the best MarketWatch.com experience, please update to a modern browser.